Deutsche Bank has no plans to curtail the independence of its research after a controversial report prompted CEO Christian Sewing to call US Treasury Secretary Scott Bessent https://t.co/BY04tCfMg1 ...

Deutsche Bank closed out a record year for profit with higher trading income and announced a new share buyback, a day after a raid on the lender’s Frankfurt offices https://t.co/JjybQDjDSX ...

Banks led by Deutsche Bank have begun marketing a $550 million junk bond that will help fund TreeHouse Foods’s pending buyout, bringing planned financing for the deal to $1.8 billion https://t.co/3CMfGeGvzw ...

Group 1 - Clorox Company is recognized as one of the Best Low Risk Stocks for a Retirement Stock Portfolio [1] - Deutsche Bank raised its price target for Clorox from $110 to $114 while maintaining a Hold rating [2] - Clorox announced the acquisition of GOJO Industries for $2.25 billion, aiming to enhance its presence in the health and hygiene sector [3][4] Group 2 - The acquisition values GOJO at $1.92 billion, with $330 million attributed to expected tax benefits, totaling $2.25 billion [4] - Clorox plans to finance the majority of the acquisition through debt and aims to finalize the deal by the end of fiscal 2026 [4] - The acquisition is expected to generate at least $50 million in annual cost synergies once fully integrated [4] Group 3 - Clorox operates as a global producer of consumer and professional products across four main segments: Health and Wellness, Household, Lifestyle, and International [5]

Group 1 - CoreWeave, Inc. announced an expanded collaboration with Nvidia Corporation to build over 5 gigawatts of AI factories by 2030, aiming to enhance global AI adoption [1] - Nvidia invested $2 billion in CoreWeave Class A common stock at a price of $87.20 per share, indicating confidence in CoreWeave's business and growth strategy [2] - CoreWeave plans to utilize Nvidia's accelerated computing platform technology for the AI factories, with Nvidia assisting in the procurement of necessary resources for development [3] Group 2 - Following the announcement, Deutsche Bank analyst upgraded CoreWeave from Hold to Buy, raising the price target from $100 to $140 [4] - Mizuho analyst maintained a Neutral rating on CoreWeave while increasing the price target from $92 to $100 [4]

US stock futures mostly moved higher on Tuesday as tech hopes offset Trump worries, with a slide in UnitedHealth (UNH) dragging on the Dow and Wall Street weighing a long-awaited India-EU trade deal. S&P 500 futures (ES=F) rose 0.3%, while those on the tech-heavy Nasdaq 100 (NQ=F) climbed 0.7%. But Dow Jones Industrial Average futures (YM=F) dropped roughly 0.3% on the heels of gains for Wall Street indexes. Trade drama gripped markets, schooled by the Greenland crisis to stay alert even with a packed e ...

Market Overview - US stock futures showed mixed movements with S&P 500 futures rising by 0.3% and Nasdaq 100 futures climbing 0.7%, while Dow Jones Industrial Average futures fell approximately 0.3% due to a decline in UnitedHealth shares [1] - The Federal Reserve is set to begin a two-day meeting, with expectations to maintain the benchmark interest rate steady, while markets are looking for indications on future rate cuts [6] Trade Developments - The European Union and India finalized a free trade agreement after nearly two decades of negotiations, aiming to enhance economic ties and counteract US tariff policies [11][12] - The deal is projected to double EU goods exports to India by 2032, with tariffs on 96.6% of EU goods exports to India being eliminated or reduced, while the EU will cut tariffs on 99.5% of goods imported from India over seven years [14] Company Earnings and Performance - UnitedHealth's shares dropped over 15% after a quarterly profit beat, as the proposed Medicare payment rates for the next year did not meet Wall Street expectations [4] - General Motors reported a fourth-quarter earnings beat, raised its dividend, and announced a $6 billion share buyback plan [5] - Salesforce's stock increased by 2% following a $5.6 billion contract with the Army, while Intel's stock rose by 3% after a recent decline [8] Health Insurance Sector - Health insurers experienced significant stock declines in after-hours trading, with Humana's stock falling by 12.5% and CVS Health's stock dropping over 10% due to a report indicating minimal increases in Medicare payment rates [20][21] - UnitedHealth's shares fell by 8.6% ahead of its earnings report, contributing to the downward pressure on the Dow Jones [21]

Core Viewpoint - Legend Biotech Corporation (NASDAQ:LEGN) is viewed positively by analysts, with Deutsche Bank and Cantor Fitzgerald both maintaining bullish ratings and setting price targets of $60 and $74 respectively, driven by expectations of strong clinical trial results and significant sales growth in its oncology pipeline [1][4]. Group 1: Analyst Ratings and Price Targets - Deutsche Bank reiterated a Buy rating on Legend Biotech and set a price target of $60, anticipating topline results from its first in-vivo CAR T program by year-end [1]. - Cantor Fitzgerald reaffirmed an Overweight rating with a price target of $74, highlighting the expected 100% year-over-year sales increase of Carvykti to $2 billion [4]. Group 2: Clinical Development and Pipeline - Initial preclinical data indicate robust dose-dependent CAR-T expansion in non-human primates, with sustained peripheral B-cell elimination observed from day 8 to day 36, suggesting in vivo CAR-T cells have properties akin to traditional CAR-T treatments [2]. - Legend Biotech aims to achieve profitability by 2026 while continuing to develop its pipeline, focusing on in vivo and allogeneic CAR-T therapies [3]. Group 3: Company Overview - Legend Biotech is a global clinical-stage biotechnology company dedicated to discovering, developing, and commercializing novel cell therapies, primarily targeting cancer and severe diseases, leveraging technologies like CAR-T cell therapy [5].

Core Viewpoint - Deutsche Bank analyst David Begleiter downgraded Sherwin-Williams (SHW) to Hold from Buy, with a price target reduced to $380 from $390, indicating a fair valuation slightly above historical averages [1] Financial Performance - Sherwin-Williams is expected to experience its third consecutive year of earnings growth below 10% in 2026, which raises concerns about its growth trajectory [1] - The analyst suggests that until Sherwin-Williams can demonstrate a return to earnings growth above 10%, the valuation multiple is likely to trend downward [1]

Group 1 - Capital One Financial Corp's shares have decreased by 4.2%, trading at $225.61, following a fourth-quarter profit miss and the announcement of acquiring startup Brex for $5.15 billion [1] - Despite the recent decline, analysts remain optimistic, with 18 out of 22 maintaining a "buy" or better rating, and a 12-month consensus target price of $278.91, indicating a 24.2% upside potential from current levels [2] - The stock has experienced a 23.5% gain over the past nine months, although it has retreated from its all-time high of $259.63, breaking below the 100-day moving average [3] Group 2 - Options trading volume for Capital One is significantly high, at three times the typical amount, with 12,000 calls and 8,023 puts traded, indicating increased market activity [4] - The most active options contract is the weekly 1/23 232.50-strike call, with new positions being opened, suggesting a strategic move by investors [4] - The current Schaeffer's Volatility Index (SVI) for Capital One is at 33%, which is higher than 84% of readings from the past year, indicating that options are affordably priced [4]